Humana (NYSE:HUM) Given New $360.00 Price Target at Cantor Fitzgerald

Humana (NYSE:HUM) had its price target trimmed by Cantor Fitzgerald from $391.00 to $360.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a neutral rating on the insurance provider’s stock. Cantor Fitzgerald also issued estimates for Humana’s FY2024 earnings at $16.04 EPS.

A number of other equities analysts also recently issued reports on HUM. Truist Financial reiterated a hold rating and issued a $550.00 price objective on shares of Humana in a report on Friday, January 19th. StockNews.com cut Humana from a strong-buy rating to a hold rating in a research report on Friday, January 26th. Stephens dropped their target price on Humana from $550.00 to $430.00 and set an overweight rating on the stock in a research report on Friday, January 26th. Bank of America reissued a neutral rating and issued a $342.00 target price (down from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Finally, The Goldman Sachs Group decreased their price objective on Humana from $450.00 to $385.00 and set a buy rating on the stock in a research note on Wednesday, April 3rd. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $433.74.

Humana Trading Down 1.1 %

Shares of Humana stock traded down $3.53 during midday trading on Thursday, reaching $307.88. 468,188 shares of the company’s stock traded hands, compared to its average volume of 1,985,533. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.59 and a current ratio of 1.67. The company has a market cap of $37.15 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 1.85 and a beta of 0.45. The stock has a 50 day moving average of $328.56 and a 200-day moving average of $395.71. Humana has a 12 month low of $299.23 and a 12 month high of $541.21.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. The business had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $9.38 earnings per share. As a group, equities analysts expect that Humana will post 16.06 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.15%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio is currently 22.04%.

Insider Activity at Humana

In other Humana news, Director Jorge S. Mesquita bought 545 shares of Humana stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, with a total value of $200,064.05. Following the transaction, the director now directly owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.32% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Humana

Large investors have recently bought and sold shares of the business. Rakuten Securities Inc. acquired a new position in shares of Humana during the fourth quarter valued at approximately $25,000. Gradient Investments LLC grew its position in Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 40 shares during the period. Cetera Trust Company N.A purchased a new position in Humana in the fourth quarter worth approximately $28,000. Private Wealth Management Group LLC purchased a new position in Humana in the fourth quarter worth approximately $32,000. Finally, Nvwm LLC grew its position in Humana by 41.0% in the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after acquiring an additional 25 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.